DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for dental pulp disease — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDental pulp disease maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dental pulp disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
calcium voltage-gated channel subunit alpha1 B (CACNA1B) — CACNA1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet r16drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VFS · 2.8 Å · ligand HEXADECANE (R16). Experimental structure, not a prediction.
What the evidence adds up to
A 1992 review proposed that drugs applied at the base of cavity preparations could treat certain types of pulpitis, listing local anaesthetics, glucocorticoids, non-steroidal anti-inflammatory agents, narcotic analgesics, and antibiotics as potentially useful. The review offered no clinical data from its own studies. A 2010 review stated that the biochemical and molecular pathways of pulpal inflammation were still poorly understood, with many gaps in knowledge, and that understanding them might eventually provide opportunities for new treatments. No specific drug or trial was reported.
A 2022 study reported that the number of patients with inflammatory pulp diseases in the country studied ranged from 19.5% to 48.5% of all dental applicants. It noted that treatment of reversible pulpitis included drugs for direct pulp covering and physical factors, but that few dentists used these methods in daily practice. No efficacy data for any drug were given. A 2024 review described pulpitis as triggered by microbial invasion, leading to complex immune and non-immune cell signalling via cytokines, chemokines, neuropeptides, proteases, and reactive species, and stated that inflammation can progress to irreversible damage and necrosis if untreated. It concluded that elucidating links between signalling pathways, symptoms, and spatiotemporal spread is essential to develop novel therapeutic strategies, but provided no drug-specific results.
Across these four papers, no clinical trial data, response rates, survival figures, or sample sizes for any drug treatment of dental pulp disease are reported. The literature remains at the stage of reviewing mechanisms and proposing future study. What is still missing are funded clinical trials with standardised diagnostic criteria for reversible versus irreversible pulpitis, validated outcome measures for pulp vitality, and patient stratification by aetiology and symptom duration.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dental Traumatology · 1992 · 20 citations
Medication of the dental pulp: a review and proposals
AbstractFor years, dentists have desired to treat the intact dental pulp. Since it is well-known that many substances, including some drugs, are capable of permeating dentin, we believe it is possible to treat certain types of pulpitis by applying drugs at the base of cavity preparations. Useful drugs include local anesthetics to block pain transmission, glucocorticoids or non-steroidal anti-inflammatory agents (NSAIA) to treat inflammation, NSAIA or narcotic analgesics for pain control, and antibiotics to treat infection. The literature is reviewed and proposals are presented to study medication of the dental pulp.
Journal of Clinical Pediatric Dentistry · 2010 · 3 citations
Dental Pulp Neuropathophysiology
AbstractMechanisms of pulpal pathophysiology are complex and the low compliance environment in which the dental pulp is allocated, further enhances the complexity of this process. Although it is known that it involves the interaction of the immune cells, pulpal cells, cytokines, chemokines and multiple neuropeptides but still there are many gaps in our current knowledge. The understanding of the biochemical and molecular pathways involved in the pulpal inflammation is important so that it can be used clinically to keep the dental pulp vital and healthy. It may thus provide an opportunity to develop potentially new treatment modalities for the inflamed dental pulp in future.
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
BIOLOGICAL METHODS OF TREATMENT OF PULPITIS
Abstract<em>In our country, the number of patients with inflammatory diseases of the pulp, according tovarious authors, ranges from 19.5 % to 48.5% of all applicants for dental help. In the treatment of reversible forms of pulpitis, along with the use of drugs for direct covering the pulp, the complex of therapeutic measures includes various physical factors, contributing to the relief of inflammation and increasing the regenerative capacity of tissues, but as the study showed, a small number of doctors apply this in their daily dental practice.</em>
University of Regensburg Publication Server (University of Regensburg) · 2024 · 0 citations · open access
Understanding dental pulp inflammation: from signaling to structure
AbstractThe pulp is a unique tissue within each tooth that is susceptible to painful inflammation, known as pulpitis, triggered by microbial invasion from carious lesions or trauma that affect many individuals. The host response involves complex immunological processes for pathogen defense and dentin apposition at the site of infection. The interplay of signaling between the immune and non-immune cells via cytokines, chemokines, neuropeptides, proteases, and reactive nitrogen and oxygen species leads to tissue reactions and structural changes in the pulp that escalate beyond a certain threshold to irreversible tissue damage. If left untreated, the inflammation, which is initially localized, can progress to pulpal necrosis, requiring root canal treatment and adversely affecting the prognosis of the tooth. To preserve pulp vitality and dental health, a deeper understanding of the molecular and cellular mechanisms of pulpitis is imperative. In particular, elucidating the links between signaling pathways, clinical symptoms, and spatiotemporal spread is essential to develop novel therapeutic strategies and push the boundaries of vital pulp therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
